277 related articles for article (PubMed ID: 1988362)
1. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of new serum tumor markers CA M26 and CA M29 in patients with primary breast cancer.
Eskelinen M; Tikanoja S; Brown J
Anticancer Res; 1990; 10(4):959-62. PubMed ID: 2382995
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CA M26, CA M29, CA 15-3 and CEA as circulating tumor markers in breast cancer patients.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Schwartz DC
Tumour Biol; 1991; 12(2):82-90. PubMed ID: 2028182
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of serum CA549, CA M26 and CA M29 levels in the post-operative follow-up of breast cancer patients.
Nicolini A; Ferdeghini M; Colombini C; Carpi A
J Nucl Med Allied Sci; 1990; 34(4):309-13. PubMed ID: 2090796
[TBL] [Abstract][Full Text] [Related]
5. Correlation between changes in the tumour markers CA-M26 and CA-M29 and standard response evaluation in patients with metastatic breast cancer.
van der Gaast A; Hulshof C; Kok TC; van Loon E; Splinter TA
Eur J Cancer; 1993; 29A(6):870-3. PubMed ID: 8484981
[TBL] [Abstract][Full Text] [Related]
6. Use of serum tumor markers in the differential diagnosis between ovarian and colorectal adenocarcinomas.
Yedema CA; Kenemans P; Wobbes T; Thomas CM; Bon GG; Mulder C; Voorhorst FJ; Verstraeten AA; van Kamp GJ; Hilgers J
Tumour Biol; 1992; 13(1-2):18-26. PubMed ID: 1589694
[TBL] [Abstract][Full Text] [Related]
7. Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values.
Bon GG; Kenemans P; Verstraeten R; van Kamp GJ; Hilgers J
Am J Obstet Gynecol; 1996 Jan; 174(1 Pt 1):107-14. PubMed ID: 8571992
[TBL] [Abstract][Full Text] [Related]
8. CA 549 as a marker in breast cancer.
Dnistrian AM; Schwartz MK; Greenberg EJ; Smith CA; Dorsa R; Schwartz DC
Int J Biol Markers; 1991; 6(3):139-43. PubMed ID: 1791307
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of squamous cell carcinoma antigen and ovarian carcinoma antigen (CA 125) in patients with benign and malignant diseases of the uterine cervix.
Gocze PM; Vahrson HW; Freeman DA
Oncology; 1994; 51(5):430-4. PubMed ID: 8052484
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients.
Linsley PS; Brown JP; Magnani JL; Horn D
Cancer Res; 1988 Apr; 48(8):2138-48. PubMed ID: 2450646
[TBL] [Abstract][Full Text] [Related]
11. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
[TBL] [Abstract][Full Text] [Related]
12. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
[TBL] [Abstract][Full Text] [Related]
13. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination.
Knauf S; Bast RC
Int J Biol Markers; 1988; 3(2):75-81. PubMed ID: 3243980
[TBL] [Abstract][Full Text] [Related]
14. [Clinical usefulness of CA M26 and CA M29 in breast carcinoma].
Quaranta M; Micelli G; Coviello M; Donadeo A; Lozupone A; Schittulli F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):35-8. PubMed ID: 2092146
[No Abstract] [Full Text] [Related]
15. The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix.
de Bruijn HW; Duk JM; van der Zee AG; Pras E; Willemse PH; Boonstra H; Hollema H; Mourits MJ; de Vries EG; Aalders JG
Tumour Biol; 1998; 19(6):505-16. PubMed ID: 9817980
[TBL] [Abstract][Full Text] [Related]
16. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
17. Experiences with SCC antigen, a new tumor marker for cervical carcinoma.
Meier W; Eiermann W; Stieber P; Schneider A; Fateh-Moghadam A; Hepp H
Eur J Cancer Clin Oncol; 1989 Nov; 25(11):1555-9. PubMed ID: 2591447
[TBL] [Abstract][Full Text] [Related]
18. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
Hashimoto T; Matsubara F; Mizukami Y; Miyazaki I; Michigishi T; Yanaihara N
Endocrinol Jpn; 1990 Apr; 37(2):247-54. PubMed ID: 1699752
[TBL] [Abstract][Full Text] [Related]
19. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer.
Kobayashi H; Terao T; Kawashima Y
J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]